A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Tumor Malignancies

Trial Purpose and Description

Trial Purpose

Participation Guidelines

Eligibility Criteria

Sponsor:

AstraZeneca

Dates:

September 2011

Last Updated:

Study HIC#:

1107008821

Clinicaltrials.gov ID: Yale7349468